Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05222932 · ClinicalTrials.gov registry record · Phase 1
Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1
A Phase 1 study of Melanoma and Head and Neck Squamous Cell Carcinoma, sponsored by TILT Biotherapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT05222932 is a Phase 1 study of Melanoma and Head and Neck Squamous Cell Carcinoma that is active but no longer recruiting, run by TILT Biotherapeutics. The registered enrollment target is 15 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05222932, a Phase 1 study of Melanoma and Head and Neck Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by TILT Biotherapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase 1, dose-escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with avelumab in patients with advanced solid tumors refractory to or progressing after anti-PD(L)1.
Conditions Studied
Interventions
- BIOLOGICAL TILT-123
- DRUG Avelumab
Study Locations (2)
New York
- Memorial Sloan Kettering Cancer Center - New York
Other
- Docrates Cancer Center - Helsinki
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-03-08 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05222932
The ClinicalTrials.gov registry entry for NCT05222932 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (98% lower). The listed sponsor is TILT Biotherapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which TILT-123 is the first listed.
NCT05222932 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Other.
Frequently Asked Questions
What is clinical trial NCT05222932 about?
NCT05222932 is a clinical study titled "Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1". This is a phase 1, dose-escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with avelumab in patients with advanced solid tumors refractory to or progressing after anti-PD(L)1.
What is the current status of trial NCT05222932?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2023-03-08. Estimated completion is 2026-12.
What conditions does trial NCT05222932 study?
This clinical trial studies the following conditions: Melanoma, Head and Neck Squamous Cell Carcinoma.
What interventions are being tested in trial NCT05222932?
The interventions under investigation include: TILT-123 (BIOLOGICAL), Avelumab (DRUG).
Who is sponsoring clinical trial NCT05222932?
This trial is sponsored by TILT Biotherapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05222932 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.